Shaping up nanoparticles for DNA delivery to cancer cells

Hai-Quan Mao, 2012 Johns Hopkins Nano-Bio Symposium. Photo by Mary Spiro

To treat cancer, scientists and clinicians have to kill cancer cells while minimally harming the healthy tissues surrounding them. However, because cancer cells are derived from healthy cells, targeting only the cancer cells is exceedingly difficult. According to Dr. Hai-Quan Mao of the Johns Hopkins University Department of Materials Science and Engineering, the “key challenge is between point of delivery and point of target tissue” when it comes to delivering cancer therapeutics. Dr. Mao spoke about the difficulties of specifically delivering drugs or genetic material to cancer cells at the 2012 Johns Hopkins University Nano-Bio Symposium. Scientists had originally thought they could create a “magic bullet” to patrol for cancer cells in the body. However, this has not been feasible; only 5 percent of injected nanoparticles reach the targeted tumor using current delivery techniques. Simply put, scientists need to figure out how to inject a treatment into the body and then selectively direct that treatment to cancer cells if the treatments are to work to their full potential.

With this in mind, Dr. Mao and his research team aim to optimize nanoparticle design to improve delivery to tumor cells by making the nanoparticles more stable in the body’s circulatory system. Mao’s group uses custom polymers and DNA scaffolds to create nanoparticles. The DNA serves dual purposes, as a building block for the particles and as a signal for cancer cells to express certain genes (for example, cell suicide genes). By tuning the polarity of the solvent used to fabricate the nanoparticles, the group can control nanoparticle shape, forming spheres, ellipsoids, or long “worms” while leaving everything else about the nanoparticles constant. This allows them to test the effects of nanoparticle size on gene delivery. Interestingly, “worms” appear more stable in the blood stream of mice and are therefore better able to deliver targeted DNA. Studies of this type will allow intelligent nanoparticle design by illuminating the key aspects for efficient tumor targeting.

Currently, Dr. Mao’s group is extending their fabrication methods to deliver other payloads to cancer cells. Small interfering ribonucleic acid (siRNA), which can suppress expression of certain genes, can also be incorporated into nanoparticles. Finally, Mao noted that the “worm”-shaped nanoparticles created by the group look like naturally occurring virus particles, including the Ebola and Marburg viruses. In the future, the group hopes to use their novel polymers and fabrication techniques to see if shape controls virus targeting to specific tissues in the body. This work could have important applications in virus treatment.

Story by Colin Paul, a Ph.D. student in the Department of Chemical and Biomolecular Engineering at Johns Hopkins with interests in microfabrication and cancer metastasis.

 

Cancer epidemiology: researchers take a broader approach

Elizabeth Platz at 2012 Johns Hopkins Nano-Bio Symposium. Photo by Stephanie Fraley

“Where do cancer data even come from?” This was the question posed to Dr. Elizabeth Platz prior to the 2012 Johns Hopkins University Nano-Bio Symposium. Dr. Platz is the Martin D. Abeloff, MD Scholar in Cancer Prevention and director of the Cancer Epidemiology, Prevention, & Control Training Program at the Johns Hopkins Bloomberg School of Public Health. As a cancer epidemiologist, Platz studies the frequency, distribution, and causes of cancer using data collected by the National Cancer Institute. By looking at these data, epidemiologists hope to understand why cancer occurs and what might be done to prevent it. “Cancer mortality in the US is declining and has been for some time,” Platz said. “The question is why.”

Dr. Platz and other cancer epidemiologists work on answering this “why.” Platz explained that cancer epidemiologists hypothesize why cancer rates may be high in certain segments of the population, follow a cohort of at-risk patients to see if they develop disease, and then try to figure out if some risk factor could be partially responsible for the disease. By identifying risk factors, cancer epidemiologists can influence public policy and promote preventative action.

Increasingly, cancer epidemiologists are working with researchers trying to answer basic science questions. An example of Dr. Platz’s recent interdisciplinary work involves finding tissue-based markers for prostate cancer, which could inform diagnoses and treatment decisions made by clinicians. One potential marker the researchers found is telomere length. Telomeres are repeated units on the ends of all chromosomes. Platz and her team of collaborators at Johns Hopkins showed that variability in tumor cell telomere length gave a 40-times greater risk for recurrence when compared with low telomere length variability. In the future, telomere length may be quantified following removal of a patient’s primary tumor before deciding on the next course of treatment.

Dr. Platz finished her talk by discussing the importance of having scientists in the nanobiotechnology fields work with cancer epidemiologists. Nanobiotechnology could greatly help epidemiologists measure exposure to environmental toxins and handle large amounts of data, allowing the epidemiologists to better make and test hypotheses about why cancer occurs. Future collaborations have the potential to drastically improve cancer care and patient survival rates.

Story by Colin Paul, a Ph.D. student in the Department of Chemical and Biomolecular Engineering at Johns Hopkins with interests in microfabrication and cancer metastasis.

 

Students talk cancer nanotech at Homewood March 21

Students affiliated with the Center of Cancer Nanotechnology Excellence (CCNE) and the Physical Sciences-Oncology Center (PS-OC) at Johns Hopkins University have organized a spring mini-symposium for March 21, 10 a.m. in the Hackerman Hall Auditorium at the Johns Hopkins University Homewood campus.

The student-run mini-symposiums aim to bring together researchers from across the campus affiliated with the PS-OC and CCNE. Graduate students training in these centers, both administered by Johns Hopkins Institute for NanoBioTechnology, work in various disciplines from physics to engineering to the basic biological sciences but with an emphasis on understanding cancer metastasis and developing methods for cancer diagnosis or therapy.

The invited speaker for the symposium is postdoctoral researcher Megan Ho of Duke University. Ho earned her PhD in mechanical engineering in the Wang lab in 2008. She is currently focused on developing microfluidic devices to investigate and control the fundamental reactions that form nanocomplexes for gene delivery. (10 a.m.)

Student apeakers, who will talk for 15 minutes, include:

  • Jane Chisholm (Justin Hanes lab/Ophthalmology): Cisplatin nanocomplexes for the local treatment of small cell lung cancer (10:20 a.m.)
  • Yunke Song (Jeff Wang Lab/Mechanical Engineering): Single Quantum Dot-Based Multiplexed Point Mutation Detection by Gap Ligase Chain Reaction (10:35 a.m.)
  • Andrew Wong (Peter Searson Lab/Materials Science and Engineering): Intravisation into an artificial blood vessel (10:50 a.m.)
  • Brian Keeley: (Jeff Wang Lab/Mechanical Engineering): Overcoming detection limitations of DNA methylation in plasma and serum of cancer patients through utilization of nanotechnology. (11:05 a.m.)
  • Sebastian Barretto (Sharon Gerecht Lab/Chemical and Biomolecular Engineering): Development of Hydrogel Microfibers to Study Angiogenesis (11:20 a.m.)

View the symposium flyer here. The mini-symposium is free and open to the entire Johns Hopkins University community. No RSVP is required, although seating is limited.

Johns Hopkins Physical Sciences-Oncology Center

Center of Cancer Nanotechnology Excellence

Hopkins faculty to present at American Society for NanoMedicine meeting

© Liudmila Gridina | Dreamstime.com

The American Society for NanoMedicine (ASNM) will hold its third annual meeting November 9 -11 at the Universities at Shady Grove Conference Center in Gaithersburg, Md. This year ASNM has worked closely with the Cancer Imaging Program, National Cancer Institute, and National Institutes of Health to create a conference with a special focus on nano-enabeled cancer diagnostics and therapies, and the synergy of the combination of nano-improved imaging modalities and targeted delivery.

The program also focuses on updates on the newest Food and Drug Administration, nanotoxicity, nanoparticle characterization, nanoinformatics, nano-ontology, results of the latest translational research and clinical trials in nanomedicine, and funding initiatives. This year’s keynote speaker is Roger Tsien, 2008 Nobel Prize Laureate. Numerous other speakers and breakout sessions are planned for the three day event. Two speakers affiliated with Johns Hopkins include Justin Hanes and Dmitri Artemov. Hanes is a professor of nanomedicine in the department of ophthalmology at the Johns Hopkins School of Medicine. Artemov is an associate professor of radiology/magnetic resonance imaging research, also at the School of Medicine.

The deadline for the poster abstracts is October 1. The top four posters submitted by young (pre and post doctoral) investigators will be selected to give a short 10-minute (eight slides) oral presentation on November 11.

ASNM describes itself as a “a non-profit, open, democratic and transparent professional society…focus(ing) on cutting-edge research in nanomedicine and moving towards realizing the potential of nanomedicine for diagnosis, treatment, and prevention of disease.” More information about the ASNM can be found on the Society’s official website.

 

 

Agenda set for Oct. 10 mini-symposium on cancer, nanotech

From the spring mini-symposium.

Johns Hopkins Physical Sciences-Oncology Center and Center of Cancer Nanotechnology Excellence will host a mini-symposium on Monday Oct., 10 in the Hackerman Hall Auditorium. Talks on topics related to cancer and nanotechnology begin at 9 a.m.

Speakers include:

  • 9:15 a.m.: The pulsating motion of breast cancer cell is regulated by surrounding epithelial cells. Speaker: Meng Horng Lee
  • 9:40 a.m.: Breast tumor extracellular matrix promotes vasculogenesis. Speaker: Abigail Hielscher
  • 10:00 a.m.: Attachment to growth substrate regulates expression of GDF15, an important molecule in metastatic cancer. Speaker: Koh Meng Aw Yong
  • 10:20 a.m.: Mucin 16 is a functional selectin ligand on pancreatic cancer cells. Speaker: Jack Chen
  • 10:40 a.m.: Particle tracking in vivo. Speaker: Pei-Hsun Wu

These talks are open to the entire Hopkins community. No RSVP is required. Refreshments will be served.

 

 

Breast cancer highlighted at Homewood mini-symposium

A tumor cell breaking free and entering the blood stream. (From animation by Ella McCrea, Nathan Weiss and Martin Rietveld)

Breast cancer will be topic of at least two of the talks planned for a mini-symposium October 10 on the Homewood campus.

UPDATED: Click here for updated list of talk titles.

Students from Johns Hopkins Physical Sciences-Oncology Center (PSOC) and Center of Cancer Nanotechnology Excellence (CCNE) will hold their second mini-symposium of the year on October 10 at 9 a.m. in Hackerman Hall Auditorium. The symposia, scheduled each spring and fall on the Homewood campus, encourage an exchange of ideas between PhD students and postdoctoral fellows associated with these centers. The entire Hopkins community is invited to attend, and no RSVP is required.

Some of the talk titles include, from the department of Chemical and Biomolecular Engineering, “The Pulsing Motion of Breast Cancer Cell is Regulated by Surrounding Epithelial Cells” presented by Meng Horng Lee, a PSOC postdoctoral fellow in the Denis Wirtz lab; “Breast Tumor Extracellular Matrix Promotes Vasculogenesis” presented by Abigail Hielscher, a postdoctoral fellow in the Sharon Gerecht lab; and “Mucin 16 is a Functional Selectin Ligand on Pancreatic Cancer Cells” given by Jack Chen, a pre-doctoral fellow in the lab of Konstantinos Konstantopoulos. Additional speakers include postdoctoral fellow Pei-Hsun Wu, PhD, a from the Wirtz Lab and Koh Meng Aw Yong, a pre-doctoral student affiliated with Princeton University’s Physical Sciences-Oncology Center.

The purpose of these twice a year, student run mini-symposia is to facilitate communication among researchers working in laboratories studying the mechanistic aspects of cancer spread (i.e., those affiliated with the PSOC) and those working on novel means of using nanotechnology for cancer diagnosis or treatment (i.e., those associated with the CCNE). Anjil Giri coordinated the fall mini-symposium, a PSOC pre-doctoral fellow in the Wirtz lab , with Erbil Abaci, a PSOC pre-doctoral fellow with in the Gerecht lab. Visit the INBT website (inbt.jhu.edu) for further details, as additional speakers and talk titles will be announced.

‘Just add water’ to activate freeze-dried brain cancer fighting nanoparticles

A fluorescence micrograph showing brain cancer cells producing a green fluorescent protein. DNA encoded to produce the protein was delivered to the cancer cells by new freeze-dried nanoparticles produced by Johns Hopkins biomedical engineers. Image: Stephany Tzeng/JHU

Biomedical engineers and clinicians at Johns Hopkins University have developed freeze-dried nanoparticles made of a shelf-stable polymer that only need the addition of water to activate their cancer-fighting gene therapy capabilities.

Principal investigator Jordan Green, assistant professor in the department of Biomedical Engineering at the Johns Hopkins School of Medicine, led the team that fabricated the polymer-based particles measuring 80 to 150 nanometers in diameter. Each particle, which is about the size of a virus, has the ability to carry a genetic cocktail designed to produce brain cancer cell-destroying molecules. After manufacture, the nanoparticles can be stored for up to 90 days before use. In principle, cancer therapies based on this technology could lead to a convenient commercial product that clinicians simply activate with water before injection into brain cancer tumor sites.

Because this method avoids the common, unpleasant side effects of traditional chemotherapy, “nanoparticle-based gene therapy has the potential to be both safer and more effective than conventional chemical therapies for the treatment of cancer,” Green said. But, he added current gene therapy nanoparticle preparations are just not practical for clinical use.

“A challenge in the field is that most non-viral gene therapy methods have very low efficacy. Another challenge with biodegradable nanoparticles, like the ones used here is that particle preparation typically takes multiple time-sensitive steps.” Green said. “Delay with formulation results in polymer degradation, and there can be variability between batches. Although this is a simple procedure for lab experiments, a clinician who wishes to use these particles during neurosurgery will face factors that would make the results unpredictable.”

In contrast, the nanoparticles developed by the Green lab are a freeze-dried, or “lyophilized,” formulation. “A clinician would simply add water, and it is ready to inject,” Green said. Green thinks this freeze-dried gene-delivery nanoparticle could be easily manufactured on a large scale.

Co-investigator Alfredo Quinones-Hinojosa, a Johns Hopkins Hospital clinician-scientist and associate professor in the departments of Neurosurgery and Oncology at the Johns Hopkins School of Medicine, said he could imagine particles based on this technology being used in conjunction with, and even instead of, brain surgery. “I envision that one day, as we understand the etiology and progression of brain cancer, we will be able to use these nanoparticles even before doing surgery,” Quinones said. “How nice would that be? Imagine avoiding brain surgery all together!”

Currently, patients with glioblastoma, or brain cancer, only have a median survival of about 14 months, Green said. “Methods other than the traditional chemotherapy drugs and radiation—or in combination with them—may improve prognosis,” he said.

Gene therapy approaches could also be personalized, Green said. “Because gene therapy can take advantage of many naturally-existing pathways and can be targeted to the cancer type of choice through nanoparticle design and transcriptional control, several levels of treatment specificity could be provided,” Green said.

The nanoparticles self-assemble from a polymer structural unit, so fabrication is fairly simple, said Green. Finding the right polymer to use, however, proved to be a challenge. Lead author Stephany Tzeng, a PhD student in biomedical engineering in Green’s lab screened an assortment of formulations from a “polymer library” before hitting on a winning combination.

“One challenge with a polymer library approach is that there are many polymers to be synthesized and nanoparticle formulations to be tested. Another challenge is designing the experiments to find out why the lead formulation works so well compared to other similar polymers and to commercially available reagents,” Green said.

Tzeng settled on a particular formulation of poly(beta-amino ester)s specifically attracted to glioblastoma (GB) cells and to brain tumor stem cells (BTSC), the cells responsible for tumor growth and spread. “Poly(beta-amino ester) nanoparticles are generally able to transfect many types of cells, but some are more specific to GBs and BTSCs,” Tzeng said.

The nanoparticles work like a virus, co-opting the cell’s own protein-making machinery, but in this case, to produce a reporter gene (used to delineate a tumor’s location) or new cancer fighting molecule. “It is possible that glioblastoma-derived cells, especially brain tumor stem cells, are more susceptible to our gene delivery approach because they divide much faster,” Tzeng added.

Not only are the particles convenient to use, the team discovered that dividing cells continued to make the new protein for as long as six weeks after application. “The gene expression peaked within a few days, which would correspond to a large initial dose of a therapeutic protein,” said Green. “The fact that gene expression can continue at a low level for a long time following injection could potentially cause a sustained, local delivery of the therapeutic protein without requiring subsequent injection or administration. The cells themselves would act as a ‘factory’ for the drug.”

Once the nanoparticles release their DNA cargo, Tzeng said the polymer quickly degrades in water, usually within days. “From there, we believe the degradation products are processed and excreted with other cellular waste products,” Tzeng said.

Members of the Green Lab are now working on identifying the intracellular mechanism responsible for facilitating cell-specific delivery. “We also plan to build additional levels of targeting into this system to make it even more specific. This includes modifying the nanoparticles with ligands to specifically bind to glioblastoma cells, making the DNA cargo able to be expressed only in GB cells, and using a DNA sequence whose product is only effective in GB cells.”

So far, the team has only successfully transfected brain tumor stem cells using these nanoparticles in a plastic dish. The next step is to test the particle in animal models.

“We hope to begin tests in vivo in the near future by implanting brain tumor stem cells into a mouse and injecting particles. We also hope to begin using functional genes that would kill cancer cells in addition to the fluorescent proteins that serve only as a marker,” Tzeng said.

Other authors who contributed to this work are Hugo Guerrero-Cázares, postdoctoral fellow in Neurosurgery and Oncology, and Joel Sunshine, an M.D.-Ph.D. candidate, and Elliott Martinez, an undergraduate leadership alliance summer student, both from Biomedical Engineering. Funding for this work came from the National Institutes of Health, Howard Hughes Medical Institute, the Robert Wood Johnson Foundation and a pilot-grant from Johns Hopkins Institute for NanoBioTechnology (INBT). Green is an affiliated faculty member of INBT. The research will be published in Issue #23 (August 2011) of the journal Biomaterials and is currently available online.

Freeze-dried gene therapy system avoids virus, complications

Story by Mary Spiro

 

Hopkins alumni learn about engineering in oncology

Denis Wirtz directs INBT’s Engineering in Oncology Center. Photo: Mary Spiro

As  part of Johns Hopkins Alumni Weekend 2011, Denis Wirtz, director of the Johns Hopkins Engineering in Oncology Center, gave a talk April 29 on how researchers are using physics and engineering to better understand cancer. Wirtz is the Theophilus H. Smoot Professor in the Whiting School of Engineering Department of Chemical and Biomolecular Engineering.

Wirtz spoke in Mason Hall Auditorium with about 100 alumni in attendance. He showed animations explaining the process of metastasis and concluded his remark with a viewing of the short movie “INBT: An Overview.” The audience seemed engaged and asked several questions following Wirtz’s presentation. The talk was presented for the Class of ’61 alumni.

Johns Hopkins Engineering in Oncology Center is a Physical Sciences-Oncology Center funded by the National Cancer Institute. It was established in 2009.

To see the full gallery of photos from this event, visit this link on the PS-OC  Facebook page.

Johns Hopkins Cancer Nanotechnology Training Center (CNTC) launched

(Photo: Mary Spiro/INBT)

The war on cancer is fought on many fronts, even tiny, nanoscale ones. To train new scientists and engineers to combat the spread of cancer, Johns Hopkins Institute for NanoBioTechnology (INBT) has established a pre-doctoral (PhD) training program in Nanotechnology for Cancer Medicine. Together with the institute’s previously established Nanotechnology for Cancer Medicine postdoctoral fellowship, these two training programs will comprise the Johns Hopkins Cancer Nanotechnology Training Center (CNTC).

Similar to the postdoctoral program, the PhD training in nanotechnology for cancer medicine will educate graduate students to use nanotechnology solutions to diagnose, treat, manage, and hopefully one day, even cure cancer, said the CNTC’s director Denis Wirtz, the Theophilus H. Smoot professor of Chemical and Biomolecular Engineering in the Whiting School of Engineering.

The CNTC was funded by a $1.8 million grant over five years from the National Cancer Institute. Launched in the fall of 2010, the pre-doctoral training program has already attracted highly qualified students with bachelor’s degrees in diverse backgrounds such as biochemistry, genetics, molecular and cellular biology, as well as those who majored in engineering or physics. By attracting students with these sorts of educational backgrounds, Wirtz said, INBT will help develop what he calls “hybrid scientists, engineers, and clinicians.”

“We are seeking to train people who can develop new nanoscale materials and nanoparticles that will address biological functions related to the growth and spread of cancer, or metastasis, at a mechanistic level,” said Wirtz, who also directs INBT’s Engineering in Oncology Center and is INBT’s associate director.

Anirban Maitra, professor of pathology and oncology at the Johns Hopkins School of Medicine and co-director of the CNTC, said research will focus on the identification and preclinical validation of the most cancer-specific nanotechnology based therapies, particularly using the wealth of knowledge on the cancer genome emerging from CNTC participant scientists such as Kenneth Kinzler and Bert Vogelstein, both School of Medicine faculty.

“The CNTC is uniquely poised to leverage this information for developing molecularly targeted nanotechnology-based tools for cancer therapy,” Maitra added.

Much like INBT’s other training programs, students seeking a doctorate specialization in nanotechnology for cancer medicine must jump through a few additional hoops than those students enrolled in traditional department-based pre-doctoral programs.

For example, in addition to the PhD requirements set forth by students’ home departments, CNTC fellows also complete two core nanotechnology courses, two intensive laboratory “boot camps”, one laboratory course designed to develop their skills in experimental and theoretical fundamentals in surface and materials science for biology and medicine, and one course in advanced cancer biology. Students must also complete two complementary laboratory rotations within their first year, participate in a professional development seminars, attend clinical conferences on cancer, among many other requirements. These extra steps set INBT trainees apart by giving them a more advanced skill set and making graduates more desirable in the job market, Wirtz said.

Generally, fellows take five to six years to complete the cancer nanotechnology for medicine PhD program. INBT will support CNTC trainees for two years, after which, the students will be funded by their primary departments from which their degrees will be conferred.

As many as six outstanding pre-doctoral fellows may enter the CNTC program per year. Candidates from under-represented groups in the science and engineering disciplines, including women and minorities, are encouraged to apply.

For more information about how to apply for the CNTC programs, please contact INBT’s Academic Program Administrator, Ashanti Edwards, at Ashanti@jhu.edu.

Johns Hopkins Physical Sciences-Oncology Center

Center of Cancer Nanotechnology Excellence

Story by Mary Spiro

 

Agenda, workshops set for Johns Hopkins cancer nanotech symposium

Hands-on workshops are part of this year’s INBT symposium. (Photo: Marty Katz/baltimorephotographer.com)

Cancer Nanotechnology forms  the focus of the fifth annual symposium for Johns Hopkins Institute for NanoBioTechnology (INBT), May 12 and 13, 2011 at the university’s Homewood campus. Friday, May 13 will feature a symposium with talks from a slate of faculty experts in nanotechnology, oncology, engineering and medicine, while hands-on workshops will be offered to small groups on Thursday, May 12.

Registration begins at 8:30 a.m. in Shriver Hall Auditorium. A poster session begins at 1:30 p.m. upstairs in the Clipper Room showcasing research from INBT affiliated faculty laboratories across several Johns Hopkins University divisions. Past symposiums have attracted as many as 500 attendees and more than 100 research posters. To register and to submit a poster, click here.

Agenda

Cancer Nanotechnology: The annual symposium of Johns Hopkins Institute for NanoBioTechnology

May 13, 2011, Shriver Hall

8:30-9:00 am: Registration, Lobby of Shriver Hall

9:00-9:05 am: Welcome/Introduction of Speakers, Denis Wirtz

9:05-9:35 am: “Why develop sensitive detection systems for abnormal DNA methylation in cancer?”

Stephen Baylin is Deputy Director, Professor of Oncology and Medicine, Chief of the Cancer Biology Division and Director for Research of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

9:35-9:55 am: “Enabling cancer drug delivery using nanoparticles”

Anirban Maitra is a professor at Johns Hopkins School of Medicine with appointments in Pathology and Oncology at the Sol Goldman Pancreatic Research Center and secondary appointments in Chemical and Biomolecular Engineering at the Whiting School of Engineering and the McKusick-Nathans Institute of Genetic Medicine. Maitra co-directs Johns Hopkins Cancer Nanotechnology Training Center and is a project director in the CCNE.

9:55-10:15 am: “Epithelial Morphogenesis in Cancer Metastasis”

Gregory Longmore is a professor at the Washington University in St. Louis School of Medicine, Department of Medicine, Oncology Division, Molecular Oncology Section and the Department of Cell Biology and Physiology. Longmore is a project co-director at Johns Hopkins Physical Sciences-Oncology Center (PS-OC).

10:15-10:35 am: “A Translational Nanoparticle-Based Imaging Method for Cancer”

Martin Pomper is a professor at Johns Hopkins School of Medicine with a primary appointment in Radiology and secondary appointments in Oncology, Radiation Oncology, and Pharmacology and Molecular Sciences, as well as Environmental Health Sciences at the Johns Hopkins Bloomberg School of Public Health. Pomper co-directs Johns Hopkins Center of Cancer Nanotechnology Excellence (CCNE)

10:35-10:50 am: Break

10:50-10:55 am: Welcome/Introduction of Speakers, Anirban Maitra

10:55-11:15 am: “Cancer Cell Motility in 3-D”

Denis Wirtz is the Theophilus H. Smoot Professor of Chemical and Biomolecular Engineering in the Whiting School of Engineering at Johns Hopkins University. Wirtz is associate director of INBT and director of the Johns Hopkins Physical Sciences-Oncology Center, also known as the Engineering in Oncology Center. He has a secondary appointment in Oncology at the Johns Hopkins School of Medicine.

11:15-11:35 am: “MRI as a Tool for Developing Vaccine Adjuvants”

Hy Levitsky is a professor of Oncology, Medicine and Urology at the Johns Hopkins School of Medicine and the Scientific Director of the George Santos Bone Marrow Transplant Program. Levitsky is a project director at the Center of Cancer Nanotechnology Excellence (CCNE).

11:35-11:55 am: “Genetically Encodable FRET-based Biosensors for probing signaling dynamics”

Jin Zhang is an associate professor at Solomon H. Snyder Department of Neuroscience at Johns Hopkins School of Medicine with primary appointments in Pharmacology and Molecular Sciences and secondary appointments in Neuroscience, Oncology, and Chemical and Biomolecular Engineering.

11:55-12:00 pm: Adjourn/Concluding Remarks, Thomas Fekete, director of corporate partnerships, INBT

12:00-1:30 pm: Break

1:30-3:30 pm: Research Poster Session, Clipper Room, Shriver Hall

Workshops give hands-on experience to nano-bio researchers

In conjunction with the fifth annual symposium talks and poster session, Johns Hopkins Institute for NanoBioTechnology will hold hands-on laboratory workshops to introduce some of the methods developed by affiliated faculty. Space is limited to participate in the workshops, which will be held the afternoon of May 12 at INBT’s headquarters in Suite 100 of the New Engineering Building. Times, instructors and topics are listed below. If you are interested in signing up for one or more of the workshops, please contact INBT’s administrative coordinator Tracy Smith at TracyINBT@jhu.edu or call 410-516-5634.

For more information about INBT’s symposium go to: http://inbt.jhu.edu/outreach/symposium/twentyeleven/

Session A: 1-3 pm

1. Electrospinning of polymeric nanofibers for tissue engineering application: Nanofibrous materials are increasingly used in tissue engineering and regenerative medicine applications and for local delivery of therapeutic agents. Electrospinning is the most widely used method for producing nanofiber matrices because of its high versatility and capacity to generate nanofibers from a variety of polymer solutions or melts. It can generate fibers with diameters ranging from tens of nanometers to a few microns. This workshop will review the basic principle of electrospinning, investigate the effect of several key parameters on fiber generation, demonstrate the method to generate nanofiber mesh and nanofiber conduits, and discuss the potential applications for tissue engineering and repair.

Instructors: Russell Martin and Hai-Quan Mao (Mao Lab)

2. Particle tracking microrheology: This hands-on course will teach participants the fundamentals and applications of high-throughput approaches to cytometry, including cell morphometry and microrheology. These approaches are being used for rapid phenotyping of cancer cells.

Instructors: Wei-Chiang Chen, Pei-Hsun Wu, and Denis Wirtz (Wirtz Lab)

Session B: 3:30-5:30 pm

3. Synthesis of quantum dots for bioengineering: This workshop will provide a hands-on approach to the synthesis of CdSe QD cores and how to purify these cores from excess surfactant. A brief discussion how to successfully electrically passivate the cores will follow. Participants will be able to water solubilize core/shell QDs using pegylated lipids. Several methods for characterizing the QDs through the synthesis and water solubilization will be performed.

Instructors: Charli Dvoracek, Justin Galloway, and Jeaho Park (Searson Lab)

4. Microfluidics for studying cell adhesion: This workshop will focus on fabrication of an “artificial blood vessel” via photolithography to generate a micron-sized (cross-section) channel. The micro-channel will be connected to a syringe pump to initiate fluid flow simulating the blood flow inside a blood vessel. This tool can be used to study how cancer cells interact with “blood vessel” surface when coated with adhesion proteins.

Instructors: Tommy Tong and Eric Balzer (K. Konstantopoulos Lab)

Story by Mary Spiro